HKSE - Delayed Quote • HKD
China Regenerative Medicine International Limited (8158.HK)
At close: April 17 at 2:59 PM GMT+8
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
180,525.000
231,612.000
282,897.000
182,136.000
Cost of Revenue
134,275.000
193,989.000
215,170.000
140,328.000
Gross Profit
46,250.000
37,623.000
67,727.000
41,808.000
Operating Expense
46,998.000
32,608.000
50,047.000
79,337.000
Operating Income
-748.000
5,015.000
17,680.000
-37,529.000
Net Non Operating Interest Income Expense
-1,069.000
-780.000
-725.000
-17,883.000
Pretax Income
-1,262.000
8,267.000
64,292.000
-142,099.000
Tax Provision
-1,939.000
3,712.000
12,465.000
12,380.000
Net Income Common Stockholders
677.000
4,555.000
13,348.000
-404,226.000
Diluted NI Available to Com Stockholders
677.000
4,555.000
13,348.000
-404,226.000
Basic EPS
0.01
0.02
0.10
-2.80
Diluted EPS
0.01
0.02
0.10
-2.80
Basic Average Shares
285,429.000
285,429.000
285,429.000
160,677.200
Diluted Average Shares
285,429.000
285,429.000
285,429.000
160,677.200
Total Expenses
181,273.000
226,597.000
265,217.000
219,665.000
Net Income from Continuing & Discontinued Operation
677.000
4,555.000
13,348.000
-404,226.000
Normalized Income
998.750
4,234.000
15,968.410
-49,452.750
Interest Income
9.000
1.000
11.000
23.000
Interest Expense
1,078.000
781.000
736.000
18,524.000
Net Interest Income
-1,069.000
-780.000
-725.000
-17,883.000
EBIT
-184.000
9,048.000
65,028.000
-123,575.000
EBITDA
-184.000
9,219.000
65,106.000
-121,844.000
Reconciled Cost of Revenue
134,275.000
193,989.000
215,170.000
140,328.000
Reconciled Depreciation
--
171.000
78.000
1,731.000
Net Income from Continuing Operation Net Minority Interest
677.000
4,555.000
51,827.000
-119,877.000
Total Unusual Items Excluding Goodwill
-429.000
428.000
44,483.000
-93,899.000
Total Unusual Items
-429.000
428.000
44,483.000
-93,899.000
Normalized EBITDA
245.000
8,791.000
20,623.000
-27,945.000
Tax Rate for Calcs
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
-107.250
107.000
8,624.410
-23,474.750
12/31/2020 - 7/18/2001
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade